Drug Profile
Research programme: antiviral monoclonal antibodies - MacroGenics
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator MacroGenics
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chikungunya virus infections; Dengue; Influenza A virus H5N1 subtype; Smallpox
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Chikungunya-virus-infections in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Dengue in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Influenza-A-virus-H5N1-subtype in USA (Parenteral)